Kura Oncology, Inc. (NASDAQ:KURA) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 18.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 298,662 shares of the company's stock after acquiring an additional 45,892 shares during the quarter. Russell Investments Group Ltd. owned about 0.38% of Kura Oncology worth $2,601,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KURA. Rhenman & Partners Asset Management AB grew its stake in shares of Kura Oncology by 88.9% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 314,526 shares of the company's stock worth $2,740,000 after purchasing an additional 148,000 shares during the period. Wells Fargo & Company MN grew its position in Kura Oncology by 48.5% during the fourth quarter. Wells Fargo & Company MN now owns 34,989 shares of the company's stock worth $305,000 after buying an additional 11,427 shares during the period. ExodusPoint Capital Management LP increased its holdings in Kura Oncology by 440.7% in the fourth quarter. ExodusPoint Capital Management LP now owns 297,234 shares of the company's stock valued at $2,589,000 after buying an additional 242,263 shares in the last quarter. Trexquant Investment LP lifted its position in shares of Kura Oncology by 867.8% during the 4th quarter. Trexquant Investment LP now owns 566,945 shares of the company's stock valued at $4,938,000 after acquiring an additional 508,362 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on KURA. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. JMP Securities restated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. UBS Group decreased their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. BTIG Research downgraded shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Finally, StockNews.com upgraded shares of Kura Oncology from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Kura Oncology presently has an average rating of "Moderate Buy" and a consensus price target of $25.50.

Kura Oncology Trading Up 3.8 %

Shares of NASDAQ:KURA traded up $0.24 during trading on Wednesday, reaching $6.55. The stock had a trading volume of 201,035 shares, compared to its average volume of 1,143,073. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $529.10 million, a P/E ratio of -2.78 and a beta of 0.83. The business has a fifty day moving average price of $6.99 and a 200-day moving average price of $10.23. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is owned by company insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.